Clinical Trial Update: Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors [Phase 1]

View source ↗

Summary

This clinical trial update reports a Phase 1 dose-determining study of EXS74539 (REC-4539) in participants with select solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Prostate Cancer
• Renal Cell Carcinoma
• Small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• EXS74539 (REC-4539)

Snippet

Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Conditions: Solid Tumor, Small Cell Lung Cancer (SCLC) | Phase 1 | Status: RECRUITING